Norvir (Ritonavir) Oral Powder shortage
Possibly permanent — AbbVie, the only company we could find listing ritonavir oral powders, has told the FDA it is discontinuing its product as of Oct 5, 2026. The FDA lists this under “To be discontinued”. We could not confirm another company listing the same medicine in the FDA NDC Directory, so talk with your prescriber about a long-term plan before your supply runs out.
AbbVie is stopping production of Norvir (ritonavir) oral powder 100 mg, and this change may be permanent. No other manufacturers of this form are listed, so there is currently no reported available source.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this medicine? See the ‘What to do’ note from Dr. Brian Staiger, PharmD →Is Norvir still in shortage? — status as of Oct 5, 2026
Still listed as “To be discontinued” as of Oct 5, 2026. We could not find another company that sells ritonavir oral powders, so this may become permanent. Talk with your prescriber about a long-term plan before your supply runs out.
The charts count only the companies that reported this shortage to the FDA; companies that haven’t reported a problem are in the green card, and the Supply-Risk rating counts them too.
Shortage timeline
-
Jul 24, 2026Currently in shortage1 of 1 product affected.
-
Jul 24, 2026First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which Norvir products are affected — by company
Company: AbbVie Inc. 📞 800-633-9110 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Norvir Oral Powder, 100 mg | 100 mg | — | Discontinuation of the manufacture of the drug | — |
These rows are company reports to the FDA for Ritonavir Oral Powder — they do not cover every company that lists this medicine. A company appears here only if it told the FDA it has a supply problem, so other companies may still have stock. That’s the basis for the Where else can I get Norvir or its generic? options further down this page.
Why is AbbVie discontinuing Norvir?
AbbVie, the maker of Norvir oral powder, has let the FDA know that they are permanently stopping the manufacture of this specific product — the 100 mg oral powder (the 30-count package). This isn't a temporary hold-up at the factory or a short-term supply problem; they are discontinuing it for good.
It's worth knowing that AbbVie did not share a specific public reason why they made this decision — just that the manufacturing of this particular form is ending. This report covers only AbbVie's oral powder version of Norvir, so it doesn't necessarily reflect the availability of ritonavir in other forms or from other manufacturers.
Based on the company-reported reason(s) and notes on file with the FDA for Ritonavir Oral Powder, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as companies report changes.
What should I do if I take Norvir?
Ritonavir Oral Powder (100 mg) is currently on the FDA shortage list, and the record shows it is being discontinued.
The single strength covered here, 100 mg, has no available source reported right now. There are no other strengths of the oral powder on this record with supply, and no other maker of the oral powder is listed in our records.
The reason given is straightforward: the manufacturer (AbbVie, marketed as Norvir) has reported discontinuing manufacture of this product. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent, so planning ahead with your care team is the right step.
What you can do:
- Do not stop, skip, or change your dose on your own — keep taking your medicine as prescribed while you sort out a plan.
- Ask your pharmacy to check wholesalers and confirm whether any remaining stock can still be located, since national data may not match local shelves.
- Talk with your prescriber or pharmacist soon about a clinician-chosen path forward, such as another suitable form or product they select for you.
For reference, the manufacturer's contact number is listed on this page, though pharmacies usually make those calls. This is general information from national data and is not individualized medical advice.
- Ask your pharmacy to check other companies’ versions, other strengths, package sizes, and nearby stores — the options below are a starting point.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Norvir or its generic?
FDA shortages are company-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every company that lists ritonavir oral powders is necessarily short. Below are the other listings in the current FDA NDC Directory that are not reported in shortage: the same medicine from companies that haven’t reported a problem (the reporting company is excluded), and other dosage forms. These are generic versions of Norvir — a switch from the brand goes through your pharmacist or prescriber. Some listings are repackagers, which relabel another company’s product. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Other dosage forms of ritonavir
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 1 productclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Norvir 100 mg | AbbVie | 30 packets | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Norvir — that fall in the same broad treatment class (antivirals, hiv-specific, protease inhibitors) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Codes & classification for pharmacists and billers
Where does this data come from?
Other antiviral shortages
Norvir shortage FAQs
Is Norvir still in shortage?
Which strengths of Norvir are affected?
Which Norvir products are affected?
When will Norvir be available again?
Can I still get Norvir or its generic somewhere?
Is the brand or the generic affected?
What should I do if I take Norvir?
Still have a question about the Norvir shortage?
Ask a pharmacist about this shortage →View Ritonavir Oral Powder on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (companies listing the same ingredient & form — the "other companies" the rating counts); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.